During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials ...

Thalassemia is a serious but preventable genetic blood disorder that affects the body’s ability to produce normal haemoglobin ...

A promising target for rare liver cancer, a functional cure for multiple myeloma — and support for people with ovarian cancer.

Treatment with cemsidomide resulted in notable responses at multiple dose levels for patients with multiple myeloma ...

The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of ...

Actinium Pharmaceuticals, Inc. (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first patient was enrolled on the trial studying Iomab-ACT ...

Exicure has concluded subject enrolment in its ongoing randomised Phase II trial on GPC-100 (burixafor) in conjunction with ...

In multiple myeloma, abnormal plasma cells build up inside bone marrow -- the spongy tissue inside large bones where blood ...

Michaela Hagenhofer, general manager, commercial operations at Johnson & Johnson Innovative Medicine, explains J&J’s ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients ...

Cells have a mailing system of sorts. They can release tiny molecular balls, called extracellular vesicles (EVs), that ...

Pieter Sonneveld, MD, PhD, chair of the Erasmus MC Cancer Institute, discussed the findings of a study modeling long-term ...